This is a limited-center, open-label dose escalating phase I/IIa study of autologous T cells
expressing LVgp120duoCAR molecules in people with HIV infection. It will follow a 3+3 design.
Dose escalation decisions will be made when a minimum of three participants have completed
the safety-evaluation period (45 days) at a given dose level. Cohort 1 will undergo infusion
of a single low-dose regimen of LVgp120duoCAR-T cells. Cohort 2 will undergo non-ablative
conditioning with cyclophosphamide, followed by infusion of a single low-dose regimen of
LVgp120duoCAR-T cells. Cohort 3 will undergo non-ablative conditioning with cyclophosphamide,
followed infusion of a single high-dose regimen of LVgp120duoCAR-T cells. Following
administration of the experimental therapy, HIV medications will be paused for participants
in each group during an analytic treatment interruption.